Development and evaluation of a community-based buprenorphine treatment intervention

Aaron D. Fox, Nancy L. Sohler, Taeko Frost, Carolina Lopez, Chinazo O. Cunningham

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The majority of Americans with opioid use disorder remain out of treatment. Operating in 33 states, Washington DC, and Puerto Rico, harm reduction agencies, which provide sterile syringes and other health services to people who inject drugs, are a key venue to reach out-of-treatment opioid users. Aiming to link out-of-treatment individuals with opioid use disorder to buprenorphine treatment, we developed a community-based buprenorphine treatment (CBBT) intervention in collaboration with New York City harm reduction agencies. Methods: Intervention development included formative data collection, feasibility testing at one harm reduction agency, and pilot testing for preliminary effectiveness at a second harm reduction agency. We used a pre-post design for both feasibility and pilot testing. In the CBBT intervention, we trained harm reduction agency staff to provide (1) buprenorphine education, (2) motivational interviewing, (3) referrals to buprenorphine-prescribing doctors, and (4) treatment retention support. We assessed feasibility by measuring staff satisfaction with the intervention and changes in knowledge about buprenorphine. We assessed preliminary effectiveness by comparing rates of buprenorphine initiation among groups of harm reduction agency clients before and after intervention implementation. Results: Among staff members at the first harm reduction agency, knowledge increased from 52% correct answers pre-intervention to 79% correct post-intervention. Among clients at the second harm reduction agency, initiation of buprenorphine treatment was low and did not differ between pre- and post-intervention groups. Conclusions: The CBBT intervention was feasible and well-received, but initiation of buprenorphine treatment among harm reduction agency clients was low. More robust interventions may be necessary to increase initiation of buprenorphine treatment.

Original languageEnglish (US)
Article number23
JournalHarm Reduction Journal
Volume14
Issue number1
DOIs
StatePublished - May 12 2017

Fingerprint

Buprenorphine
Harm Reduction
Opioid Analgesics
Motivational Interviewing
Puerto Rico
Syringes
Health Services
Referral and Consultation

Keywords

  • Access to care
  • Buprenorphine
  • Harm reduction agencies
  • Opioid addiction

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Psychiatry and Mental health

Cite this

Development and evaluation of a community-based buprenorphine treatment intervention. / Fox, Aaron D.; Sohler, Nancy L.; Frost, Taeko; Lopez, Carolina; Cunningham, Chinazo O.

In: Harm Reduction Journal, Vol. 14, No. 1, 23, 12.05.2017.

Research output: Contribution to journalArticle

@article{049d582e25d640e9825b3ed5de45381b,
title = "Development and evaluation of a community-based buprenorphine treatment intervention",
abstract = "Background: The majority of Americans with opioid use disorder remain out of treatment. Operating in 33 states, Washington DC, and Puerto Rico, harm reduction agencies, which provide sterile syringes and other health services to people who inject drugs, are a key venue to reach out-of-treatment opioid users. Aiming to link out-of-treatment individuals with opioid use disorder to buprenorphine treatment, we developed a community-based buprenorphine treatment (CBBT) intervention in collaboration with New York City harm reduction agencies. Methods: Intervention development included formative data collection, feasibility testing at one harm reduction agency, and pilot testing for preliminary effectiveness at a second harm reduction agency. We used a pre-post design for both feasibility and pilot testing. In the CBBT intervention, we trained harm reduction agency staff to provide (1) buprenorphine education, (2) motivational interviewing, (3) referrals to buprenorphine-prescribing doctors, and (4) treatment retention support. We assessed feasibility by measuring staff satisfaction with the intervention and changes in knowledge about buprenorphine. We assessed preliminary effectiveness by comparing rates of buprenorphine initiation among groups of harm reduction agency clients before and after intervention implementation. Results: Among staff members at the first harm reduction agency, knowledge increased from 52{\%} correct answers pre-intervention to 79{\%} correct post-intervention. Among clients at the second harm reduction agency, initiation of buprenorphine treatment was low and did not differ between pre- and post-intervention groups. Conclusions: The CBBT intervention was feasible and well-received, but initiation of buprenorphine treatment among harm reduction agency clients was low. More robust interventions may be necessary to increase initiation of buprenorphine treatment.",
keywords = "Access to care, Buprenorphine, Harm reduction agencies, Opioid addiction",
author = "Fox, {Aaron D.} and Sohler, {Nancy L.} and Taeko Frost and Carolina Lopez and Cunningham, {Chinazo O.}",
year = "2017",
month = "5",
day = "12",
doi = "10.1186/s12954-017-0149-y",
language = "English (US)",
volume = "14",
journal = "Harm Reduction Journal",
issn = "1477-7517",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Development and evaluation of a community-based buprenorphine treatment intervention

AU - Fox, Aaron D.

AU - Sohler, Nancy L.

AU - Frost, Taeko

AU - Lopez, Carolina

AU - Cunningham, Chinazo O.

PY - 2017/5/12

Y1 - 2017/5/12

N2 - Background: The majority of Americans with opioid use disorder remain out of treatment. Operating in 33 states, Washington DC, and Puerto Rico, harm reduction agencies, which provide sterile syringes and other health services to people who inject drugs, are a key venue to reach out-of-treatment opioid users. Aiming to link out-of-treatment individuals with opioid use disorder to buprenorphine treatment, we developed a community-based buprenorphine treatment (CBBT) intervention in collaboration with New York City harm reduction agencies. Methods: Intervention development included formative data collection, feasibility testing at one harm reduction agency, and pilot testing for preliminary effectiveness at a second harm reduction agency. We used a pre-post design for both feasibility and pilot testing. In the CBBT intervention, we trained harm reduction agency staff to provide (1) buprenorphine education, (2) motivational interviewing, (3) referrals to buprenorphine-prescribing doctors, and (4) treatment retention support. We assessed feasibility by measuring staff satisfaction with the intervention and changes in knowledge about buprenorphine. We assessed preliminary effectiveness by comparing rates of buprenorphine initiation among groups of harm reduction agency clients before and after intervention implementation. Results: Among staff members at the first harm reduction agency, knowledge increased from 52% correct answers pre-intervention to 79% correct post-intervention. Among clients at the second harm reduction agency, initiation of buprenorphine treatment was low and did not differ between pre- and post-intervention groups. Conclusions: The CBBT intervention was feasible and well-received, but initiation of buprenorphine treatment among harm reduction agency clients was low. More robust interventions may be necessary to increase initiation of buprenorphine treatment.

AB - Background: The majority of Americans with opioid use disorder remain out of treatment. Operating in 33 states, Washington DC, and Puerto Rico, harm reduction agencies, which provide sterile syringes and other health services to people who inject drugs, are a key venue to reach out-of-treatment opioid users. Aiming to link out-of-treatment individuals with opioid use disorder to buprenorphine treatment, we developed a community-based buprenorphine treatment (CBBT) intervention in collaboration with New York City harm reduction agencies. Methods: Intervention development included formative data collection, feasibility testing at one harm reduction agency, and pilot testing for preliminary effectiveness at a second harm reduction agency. We used a pre-post design for both feasibility and pilot testing. In the CBBT intervention, we trained harm reduction agency staff to provide (1) buprenorphine education, (2) motivational interviewing, (3) referrals to buprenorphine-prescribing doctors, and (4) treatment retention support. We assessed feasibility by measuring staff satisfaction with the intervention and changes in knowledge about buprenorphine. We assessed preliminary effectiveness by comparing rates of buprenorphine initiation among groups of harm reduction agency clients before and after intervention implementation. Results: Among staff members at the first harm reduction agency, knowledge increased from 52% correct answers pre-intervention to 79% correct post-intervention. Among clients at the second harm reduction agency, initiation of buprenorphine treatment was low and did not differ between pre- and post-intervention groups. Conclusions: The CBBT intervention was feasible and well-received, but initiation of buprenorphine treatment among harm reduction agency clients was low. More robust interventions may be necessary to increase initiation of buprenorphine treatment.

KW - Access to care

KW - Buprenorphine

KW - Harm reduction agencies

KW - Opioid addiction

UR - http://www.scopus.com/inward/record.url?scp=85019145272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019145272&partnerID=8YFLogxK

U2 - 10.1186/s12954-017-0149-y

DO - 10.1186/s12954-017-0149-y

M3 - Article

VL - 14

JO - Harm Reduction Journal

JF - Harm Reduction Journal

SN - 1477-7517

IS - 1

M1 - 23

ER -